These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29502434)

  • 1. Using Mismatch Negativity to Investigate the Pathophysiology of Substance Use Disorders and Comorbid Psychosis.
    Ramlakhan JU; Zomorrodi R; Downar J; Blumberger DM; Daskalakis ZJ; George TP; Kiang M; Barr MS
    Clin EEG Neurosci; 2018 Jul; 49(4):226-237. PubMed ID: 29502434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced duration mismatch negativity in adolescents with psychotic symptoms: further evidence for mismatch negativity as a possible biomarker for vulnerability to psychosis.
    Murphy JR; Rawdon C; Kelleher I; Twomey D; Markey PS; Cannon M; Roche RA
    BMC Psychiatry; 2013 Feb; 13():45. PubMed ID: 23375130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch negativity and P3a amplitude in young adolescents with first-episode psychosis: a comparison with ADHD.
    Rydkjær J; Møllegaard Jepsen JR; Pagsberg AK; Fagerlund B; Glenthøj BY; Oranje B
    Psychol Med; 2017 Jan; 47(2):377-388. PubMed ID: 27776572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed preattentional functioning in early psychosis patients with cannabis use.
    Pesa N; Hermens DF; Battisti RA; Kaur M; Hickie IB; Solowij N
    Psychopharmacology (Berl); 2012 Aug; 222(3):507-18. PubMed ID: 22402706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Event-Related Potentials in the Clinical High-Risk (CHR) State for Psychosis: A Systematic Review.
    Lepock JR; Mizrahi R; Korostil M; Bagby RM; Pang EW; Kiang M
    Clin EEG Neurosci; 2018 Jul; 49(4):215-225. PubMed ID: 29382210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch negativity (MMN) as biomarker predicting psychosis in clinically at-risk individuals.
    Näätänen R; Todd J; Schall U
    Biol Psychol; 2016 Apr; 116():36-40. PubMed ID: 26542526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensory prediction errors in the continuum of psychosis.
    Randeniya R; Oestreich LKL; Garrido MI
    Schizophr Res; 2018 Jan; 191():109-122. PubMed ID: 28457774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration and frequency mismatch negativity shows no progressive reduction in early stages of psychosis.
    Koshiyama D; Kirihara K; Tada M; Nagai T; Koike S; Suga M; Araki T; Kasai K
    Schizophr Res; 2017 Dec; 190():32-38. PubMed ID: 28314681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch negativity (MMN) as a tool for translational investigations into early psychosis: A review.
    Tada M; Kirihara K; Mizutani S; Uka T; Kunii N; Koshiyama D; Fujioka M; Usui K; Nagai T; Araki T; Kasai K
    Int J Psychophysiol; 2019 Nov; 145():5-14. PubMed ID: 30831138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch negativity (MMN) deficiency: a break-through biomarker in predicting psychosis onset.
    Näätänen R; Shiga T; Asano S; Yabe H
    Int J Psychophysiol; 2015 Mar; 95(3):338-44. PubMed ID: 25562834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis.
    Atkinson RJ; Michie PT; Schall U
    Biol Psychiatry; 2012 Jan; 71(2):98-104. PubMed ID: 22000060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch negativity in tobacco-naïve cannabis users and its alteration with acute nicotine administration.
    Impey D; El-Marj N; Parks A; Choueiry J; Fisher D; Knott VJ
    Pharmacol Biochem Behav; 2015 Sep; 136():73-81. PubMed ID: 26188167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch negativity as a "translatable" brain marker toward early intervention for psychosis: a review.
    Nagai T; Tada M; Kirihara K; Araki T; Jinde S; Kasai K
    Front Psychiatry; 2013 Sep; 4():115. PubMed ID: 24069006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch negativity: no difference between controls and abstinent alcoholics.
    Fein G; Whitlow B; Finn P
    Alcohol Clin Exp Res; 2004 Jan; 28(1):137-42. PubMed ID: 14745312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forecasting psychosis by event-related potentials-systematic review and specific meta-analysis.
    Bodatsch M; Brockhaus-Dumke A; Klosterkötter J; Ruhrmann S
    Biol Psychiatry; 2015 Jun; 77(11):951-8. PubMed ID: 25636178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal auditory pattern perception in schizophrenia.
    Haigh SM; Coffman BA; Murphy TK; Butera CD; Salisbury DF
    Schizophr Res; 2016 Oct; 176(2-3):473-479. PubMed ID: 27502427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.
    Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J
    Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin Interneurons Control a Key Component of Mismatch Negativity in Mouse Visual Cortex.
    Hamm JP; Yuste R
    Cell Rep; 2016 Jul; 16(3):597-604. PubMed ID: 27396334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcohol use and mismatch negativity in young patients with psychotic disorder.
    Chitty KM; Kaur M; Lagopoulos J; Hickie IB; Hermens DF
    Neuroreport; 2011 Dec; 22(17):918-22. PubMed ID: 22009194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Event-related potentials in substance use disorders: a narrative review based on articles from 1984 to 2012.
    Campanella S; Pogarell O; Boutros N
    Clin EEG Neurosci; 2014 Apr; 45(2):67-76. PubMed ID: 24104954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.